WHO Prequalification Opens Public Procurement Path for Infant Antimalarial

Novartis has secured WHO prequalification for Coartem Baby (artemether-lumefantrine), the first antimalarial formulation developed specifically for newborns and young infants weighing 2 to 5 kilograms -- a weight band that has historically been excluded from antimalarial clinical development programs. The designation unlocks eligibility for UN and public sector procurement channels, a prerequisite for meaningful volume uptake in malaria-endemic markets across sub-Saharan Africa.

Until now, clinicians treating the smallest infants with Plasmodium infections had no weight-appropriate option. Infants under 4.5 kg were managed with formulations intended for older children, carrying documented risks of subtherapeutic dosing or elevated toxicity exposure. WHO data from 2024 recorded 282 million malaria cases and 610,000 deaths globally, with children under five accounting for approximately three in four malaria deaths in Africa. An estimated 30 million births occur annually in African malaria-risk zones, with one large West Africa survey reporting infection rates between 3.4% and 18.4% in infants under six months.

Coartem Baby was co-developed with Medicines for Malaria Venture (MMV) and advanced through the PAMAfrica consortium, co-funded by the European and Developing Countries Clinical Trials Partnership and the Swedish International Development Cooperation Agency. Novartis has indicated the product will be made available on a largely not-for-profit basis in endemic regions. A limited launch is already underway in Ghana, where field clinicians have reported improved confidence in managing neonatal malaria presentations.

Regulatory and procurement teams in endemic-country health ministries should note that WHO prequalification status positions Coartem Baby for immediate consideration under UNICEF, Global Fund, and PAHO procurement frameworks. Manufacturers and formulators tracking the artemether-lumefantrine space should monitor how this weight-band extension influences future ICH Q10-aligned development strategies for neglected pediatric populations.